A mathematical model to elucidate brain tumor abrogation by immunotherapy with T11 target structure.
T11 Target structure (T11TS), a membrane glycoprotein isolated from sheep erythrocytes, reverses the immune suppressed state of brain tumor induced animals by boosting the functional status of the immune cells. This study aims at aiding in the design of more efficacious brain tumor therapies with T1...
Main Authors: | Sandip Banerjee, Subhas Khajanchi, Swapna Chaudhuri |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4425651?pdf=render |
Similar Items
-
Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?
by: Javier Sánchez Ramírez, et al.
Published: (2019-06-01) -
Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment
by: Natasha Mupeta Kaweme, et al.
Published: (2021-06-01) -
Immunotherapy for Pediatric Brain Tumors
by: Elias J. Sayour, et al.
Published: (2017-10-01) -
Tumor Targeted Nanocarriers for Immunotherapy
by: Alejandro Baeza
Published: (2020-03-01) -
Immunotherapy Targeting Tumor-Associated Macrophages
by: Yafei Liu, et al.
Published: (2020-11-01)